Coronavirus disease 2019 (COVID‐19) is an infectious respiratory disease caused by a new strain of the coronavirus. There is limited data on the pathogenesis and the cellular responses of COVID‐19. In this study, we aimed to determine the variation of metabolites between healthy control and COVID‐19 via the untargeted metabolomics method. Serum samples were obtained from 44 COVID‐19 patients and 41 healthy controls. Untargeted metabolomics analyses were performed by the LC/Q‐TOF/MS (liquid chromatography quadrupole time‐of‐flight mass spectrometry) method. Data acquisition, classification, and identification were achieved by the METLIN database and XCMS. Significant differences were determined between patients and healthy controls in terms of purine, glutamine, leukotriene D4 (LTD4), and glutathione metabolisms. Downregulations were determined in R‐S lactoglutathione and glutamine. Upregulations were detected in hypoxanthine, inosine, and LTD4. Identified metabolites indicate roles for purine, glutamine, LTD4, and glutathione metabolisms in the pathogenesis of the COVID‐19. The use of selective leukotriene D4 receptor antagonists, targeting purinergic signaling as a therapeutic approach and glutamine supplementation may decrease the severity and mortality of COVID‐19.

With the lack of regional differences and the well-standardized status of test results, the RIs derived from this nationwide study can be used for the entire Turkish population.

No abstract

No abstract

Introduction Numerous efforts in natural product drug development are reported for the treatment of Coronavirus. Based on the literature, among these natural plants Artemisia annua L. shows some promise for the treatment of SARS‐CoV‐2. Objective The main objective of our study was to determine artemisinin content by liquid chromatography electrospray ionisation tandem mass spectrometry (LC‐ESI‐MS/MS), to investigate the in vitro biological activity of artemisinin from the A. annua plants grown in Turkey with various extracted methods, to elaborate in silico activity against SARS‐CoV‐2 using molecular modelling. Methodology Twenty‐one different extractions were applied. Direct and sequential extractions studies were compared with ultrasonic assisted maceration, Soxhlet, and ultra‐rapid determined artemisinin active molecules by LC‐ESI‐MS/MS methods. The inhibition of spike protein and main protease (3CL) enzyme activity of SARS‐CoV‐2 virus was assessed by time resolved fluorescence energy transfer (TR‐FRET) assay. Results Artemisinin content in the range 0.062–0.066%. Artemisinin showed significant inhibition of 3CL protease activity but not Spike/ACE‐2 binding. The 50% effective concentration (EC50) of artemisinin against SARS‐CoV‐2 Spike pseudovirus was found greater than 50 μM (EC45) in HEK293T cell line whereas the cell viability was 94% of the control (P < 0.01). The immunosuppressive effects of artemisinin on TNF‐α production on both pseudovirus and lipopolysaccharide (LPS)‐induced THP‐1 cells were found significant in a dose dependent manner. Conclusion Further studies of these extracts for COVID‐19 treatment will shed light to seek alternative treatment options. Moreover, these natural extracts can be used as an additional treatment option with medicines, as well as prophylactic use can be very beneficial for patients.

Objectives It is vital to determine the intensive care unit (ICU) requirement at an early stage to reduce the mortality rate in COVID-19 patients. The aim of the study was to find reliable predictive markers to determine the ICU requirement. Methods We retrospectively reviewed the clinical and laboratory records of 151 COVID-19 patients. The predictive abilities of biochemical parameters and computed tomography (CT) score were evaluated to determine of ICU requirement. Results The area under curve (AUC) values for procalcitonin, D-Dimer, C reactive protein (CRP), glucose, lactate dehydrogenase (LDH) and CT score were found higher than those for other parameters in the prediction of ICU requirement. The negative predictive values of these markers were higher than their positive predictive values. CT score was found to be highly correlated with fibrinogen and CRP. The glucose levels [odd ratio (OR): 95% CI; 1.07, p-value: 0.014] and CT score [OR: 95% CI; 1.05, p-value: 0.022] were associated with ICU requirement in COVID-19 patients. Conclusions CT score, procalcitonin, D-Dimer, CRP, glucose, and LDH are potential predictors to rule out ICU requirement on hospital admission. Fibrinogen and CRP can be used to follow up and predict lung damages in patients with COVID-19.

No abstract

Procuring valuable bioactive compounds from low quality green tea is of great interest. Green tea polysaccharides (GTPS), obtained from low quality tea leaves, were examined for their yield, monosaccharide composition, total phenolic content, antioxidant potential, and structures as well as molecular weight distribution and in vitro anti-diabetic activities. GTPS were also evaluated for their toxicity by performing cytotoxicity and genotoxicity. Additionally, 50% lethal dose (LD50) for GTPS was determined using an acute toxicity test to assess the safe use of it as a dietary supplement. Monosaccharides of GTPS were mainly composed of xylose, glucose, ribose, galactose, arabinose, and glucuronic acid. GTPS exhibited 91.86% α-glucosidase inhibition at 0.5 mg/mL concentration. The α-glucosidase inhibitory activity of GTPS was higher than that of pharmacological glucosidase inhibitor, acarbose, which exhibited only 47.86% inhibition at 2.5 mg/mL concentration. Neither cytotoxic nor no mutagenic effects were found for GTPS. The acute toxicity also showed that LD50 of GTPS was greater than 5,000 mg/kg. The present work suggests that GTPS can be considered as an anti-diabetic dietary supplement without posing any potential health risk.